Natera Inc stock (US6323071042): Wolfe Research initiation and recent price action in focus

Natera Inc shares on the Nasdaq in the United States are drawing attention after Wolfe Research started coverage with an outperform rating and a USD 260 price target, while the stock most recently closed around USD 223 and continues to trade actively in the US healthcare sector.

Natera Inc shares, listed on the Nasdaq in the United States under the ticker NTRA, remain in focus after a recent initiation of coverage by Wolfe Research with an outperform rating and a USD 260 price target, while the stock most recently closed at about USD 223 on 05/29/2026, underscoring continued interest in the US-based genetic testing specialist according to MarketBeat as of 05/29/2026 and Investing.com as of 05/25/2026.

The stock traded at USD 223.37 on 05/29/2026 on Nasdaq, unchanged on the day according to MarketBeat as of 05/29/2026, while second-line data from StockInvest.us as of 05/29/2026 indicate that the shares have risen for three consecutive sessions, reflecting a period of firmer trading conditions for the US healthcare name.

The Wolfe Research note, published on 05/25/2026, set an outperform rating and a USD 260 price target when Natera was trading near USD 218.81, with the broker stating that the target implied roughly 19 percent upside at that time, according to an analyst ratings update carried by Investing.com as of 05/25/2026.

Against this backdrop, Natera continues to be covered by a broad group of US and global banks, with MarketBeat reporting as of 05/29/2026 that 19 Wall Street analysts have a twelve-month average price target of USD 256.60 on the stock, with estimates ranging from USD 172.00 to USD 300.00 and a consensus rating described as a moderate buy.

In Germany, Natera shares can also be traded via off-exchange venues such as Tradegate in euro, offering an additional access point for investors based in Europe who are looking at US-listed healthcare growth stocks alongside their domestic holdings.

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Natera Inc
• Sector/industry: Healthcare - genetic testing and diagnostics
• Headquarters/country: Austin, United States
• Core markets: United States, Europe, selected international markets
• Key revenue drivers: Prenatal screening tests, oncology minimal residual disease tests, organ health and transplant assessment assays
• Home exchange/listing venue: Nasdaq (NTRA)
• Trading currency: USD

Natera Inc: core business model

Operating as a specialized molecular diagnostics company, Natera focuses on developing and commercializing cell-free DNA-based tests across women’s health, oncology, and organ health, with revenue primarily generated from test volumes ordered by physicians and healthcare systems that bill payers and patients for these advanced genetic analyses.

Latest quarterly results for Natera Inc at a glance

For the most recent reported quarter, Natera presented double-digit year-on-year revenue growth as it continued to scale its core genetic testing platforms, according to the company’s latest earnings release and accompanying conference call transcript filed with the SEC and hosted via its investor relations website.

The quarterly update also highlighted ongoing investment in research and development to expand clinical indications for assays such as Signatera in oncology and Panorama in prenatal testing, with management reiterating its focus on improving gross margins over time as test volumes increase and operational efficiencies are realized.

Conclusion

Natera Inc’s shares on Nasdaq are currently trading near recent highs around USD 223, supported by a steady flow of news and a robust pipeline of genetic tests in key healthcare niches. The latest Wolfe Research initiation with an outperform rating and a USD 260 price target adds to existing analyst interest, while recent quarterly figures show that the company remains focused on scaling test volumes and improving profitability over time. For investors following the US healthcare and diagnostics space, the stock’s combination of active coverage and ongoing product development continues to shape expectations for Natera’s medium-term growth path.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.